A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

NCT02968160 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

55

Enrollment

INDUSTRY

Sponsor class

Stopped Due to poor enrollment rate

Conditions

Metabolic Syndrome

Interventions

DRUG: Telmisartan 40mg + Rosuvastatin 20mg
DRUG: Telmisartan 80mg + Rosuvastatin 20mg
DRUG: Telmisartan 40mg, 80 mg
DRUG: Rosuvastatin 20mg

Sponsor

Yuhan Corporation

Collaborators

[object Object]